Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2036

Annual patent cliff calendar for 2036 — US pharmaceutical patents by expiration date.

Patents
1,428

Quick answer

1,428 indexed pharmaceutical patents have expiration dates in 2036. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 9339515

    Method for treatment of pulmonary fibrosis

    GALECTIN THERAPEUTICS, INC. · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9340594

    VEGF antagonist formulations for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9340546

    Compounds useful as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9340307

    Stable laquinimod preparations

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9339491

    Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease

    MEREO BIOPHARMA 1 LIMITED · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9339440

    Thermo-kinetic mixing for pharmaceutical applications

    The Board of Regents of the University of Texas System · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9339507

    Treprostinil administration by inhalation

    United Therapeutics Corporation · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9339459

    Particulate materials

    Nektar Therapeutics · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9339513

    Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes

    Alnylam Pharmaceuticals, Inc. · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9339469

    R(+)-N-methyl-propargyl-aminoindan

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9339482

    Methods to treat dysregulated blood glucose disorders

    Regents of the University of Minnesota · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9339495

    Methods of increasing tonic inhibition and treating secondary insomnia

    OVID THERAPEUTICS INC. · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9339528

    Methods for treating epithelium trauma of the intestinal mucosa using interleukin-1 receptor antagonist

    GENERAL REGENERATIVES, LTD. · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9340538

    Dihydropyrimidine compounds and their application in pharmaceuticals

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9340522

    Pyrazolone-derivatives and their use as PDE-4 inhibitors

    TAKEDA GMBH · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9339545

    Stable formulations for parenteral injection of peptide drugs

    XERIS PHARMACEUTICALS, INC. · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9340547

    Pyrrolotriazinone derivatives as inhibitors P13K

    Almirall, S.A. · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9339433

    Methods of diagnosing and treating neonatal reversion to fetal consciousness

    The Regents of the University of California · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9340557

    Substituted quinoxaline DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9340576

    Methods of treating depression and other related diseases

    Northwestern University · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9340572

    Taccalonolide microtubule stabilizers

    The Board of Regents of the University of Texas System · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9340612

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9340769

    Methods and compositions for treating P. acnes

    The Regents of the University of California · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9340611

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9340785

    Selective inhibition of polyglutamine protein expression

    The Board of Regents of the University of Texas System · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9340789

    UNA oligomer structures for therapeutic agents

    ARCTURUS THERAPEUTICS, INC. · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9340784

    Methods and compositions for modulating alpha-1-antitrypsin expression

    Ionis Pharmaceuticals, Inc. · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9341626

    Selective cytopheresis devices and related methods thereof

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9341619

    Hyposialylation disorders

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9340782

    Antimir-451 for the treatment of polycythemias

    The Board of Regents of the University of Texas System · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9347063

    Oligonucleotide analog and method for treating flavivirus infections

    Sarepta Therapeutics, Inc. · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9346746

    R(+)-N-formyl-propargyl-aminoindan

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9345780

    Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components

    Tekmira Pharmaceuticals Corporation · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9347951

    Fusion protein comprising the extracellular domain of a filovirus glycoprotein fused to an immunoglobulin heavy chain constant region

    The United States of America as Represented by The Secretary of the Department of Health and Human Services National Institutes of Health Office of Technology Transfer · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9346875

    Therapy for filovirus infection

    The United States of America as represented by the Secretary of the Army · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9346829

    5-HT3 receptor antagonists

    Takeda Pharmaceutical Company Limited · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9345758

    Materials and methods for respiratory disease control in canines

    The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9345726

    CD117+ cells and uses thereof

    The Regents of the University of Colorado, a Body Corporate · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9345708

    Inhibitors of influenza viruses replication

    Vertex Pharmaceuticals Incorporated · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9345790

    Cobalt-based MRI contrast agent and imaging system

    The Board of Regents of the University of Texas System · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9345775

    Compositions for targeted delivery of siRNA

    Arrowhead Madison, Inc. · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9345748

    Anti-SSX-2 T cell receptors and related materials and methods of use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9345781

    Targeted dendrimer-drug conjugates

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9345718

    Phospholipid ether analogs as cancer-targeting drug vehicles

    CELLECTAR BIOSCIENCES, INC. · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9346759

    Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor

    Almirall, S.A. · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9346765

    2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9345713

    6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD

    Takeda Pharmaceutical Company Limited · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9346776

    Fused heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2036?

1,428 published patents in our USPTO index have expiration dates falling in calendar year 2036.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.